Coadministration of the Aromatase Inhibitor Formestane and an Isopropanolic Extract of Black Cohosh in a Rat Model of Chemically Induced Mammary Carcinoma

Abstract

Non-steroidal as well as steroidal aromatase inhibitors are currently being discussed as alternatives to tamoxifen in the first-line treatment of patients with hormone-dependent breast cancer. Many of these women are in a postmenopausal state and additionally troubled by climacteric complaints. Naturally occurring symptoms like hot flushes and night sweats can be triggered or augmented by anti-hormonal drugs. At the aromatase molecule, steroidal inhibitors like exemestane and formestane compete with the hormonal precursors for the substrate binding site and inactivate the enzyme irreversibly. An isopropanolic extract of the rootstock of black cohosh (iCR), which is a common comedication of aromatase inhibitors in breast cancer patients suffering from climacteric symptoms, contains triterpene glycosides and cinnamic acid esters, both of which possess structural similarities to steroids. We therefore tested a high dose of iCR, guaranteeing an effective uptake of 60 mg herbal substance per kg body weight and shown to influence rat bone and uterus, for putative interactions with two low dosing regimens of 3.5 mg or 5.0 mg formestane per animal and day. We chose a rat model of chemically induced breast cancer and evaluated tumor growth and serum estrogen levels. Compared to a tumor area of 1400 mm² after 21 days of unopposed tumor growth, formestane treatment, irrespective of concomitant black cohosh application, significantly reduced neoplastic growth by 50 %. Formestane also significantly reduced serum estrogen levels, an effect which was also not abolished by iCR. Therefore, in this experimental setting, when challenging two low doses of formestane with a high dose of iCR, our data do not raise concerns against combining aromatase inhibitors with black cohosh.

Cimicifuga racemosa - Actaea racemosa - Ranunculaceae - aromatase inhibitor - black cohosh - formestane - mammary carcinoma - phytotherapy

References

• 1 Holmberg L, Anderson H. HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped.  Lancet. 2004;  363 453-5.
• 2 Henderson I C, Piccart-Gebhart M J. The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.  Clin Breast Cancer. 2005;  6 206-15.
• 3 Wiseman L R, Goa K L. Formestane: A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.  Drugs Aging. 1996;  9 292-306.
• 4 Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor positive human breast cancer cells.  Breast Cancer Res Treat. 2002;  76 1-10.
• 5 Nißlein T, Freudenstein J. Effect of an isopropanolic extract of Cimicifuga racemosa on urinary crosslinks and other parameters of bone quality in an ovariectomized rat model of osteoporosis.  J Bone Miner Metab. 2003;  21 370-6.
• 6 Nißlein T, Freudenstein J. Concomitant administration of an isopropanolic extract of black cohosh and tamoxifen in the in vivo tumor model of implanted RUCA-I rat endometrial adenocarcinoma cells.  Toxicol Lett. 2004;  150 271-5.
• 7 Hostanska K, Nißlein T, Freudenstein J, Reichling J, Saller R. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis.  Breast Cancer Res Treat. 2004;  84 151-60.
• 8 Hostanska K, Nißlein T, Freudenstein J, Reichling J, Saller R. Evaluation of cell death caused by triterpene glycosides and phenolic substances from Cimicifuga racemosa extract in human MCF-7 breast cancer cells.  Biol Pharm Bull. 2004;  27 1970-5.
• 9 Kretzschmar G, Nißlein T, Zierau O, Vollmer G. No estrogen-like effects of an isopropanolic extract of Rhizoma Cimicifugae racemosae on uterus and vena cava of rats after 17 day treatment.  J Steroid Biochem Mol Biol. 2005;  97 271-7.
• 10 Liske E, Hänggi W, Henneicke-von Zepelin H H, Boblitz N, Wüstenberg P, Rahlfs V W. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect.  J Womens Health Gend Based Med. 2002;  11 163-74.
• 11 Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin H H. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms.  Obstet Gynecol. 2005;  105 1074-83.
• 12 He K, Zheng B, Kim C H, Rogers L, Zheng Q. Direct analysis and identification of triterpene glycosides by LC/MS in black cohosh, Cimicifuga racemosa, and in several commercially available black cohosh products.  Planta Med. 2000;  66 635-40.
• 13 Stromeier S, Petereit F, Nahrstedt A. Phenolic esters from the rhizomes of Cimicifuga racemosa do not cause proliferation effects in MCF-7 cells.  Planta Med. 2005;  71 495-500.
• 14 Freudenstein J, Dasenbrock C, Nisslein T. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract.  Cancer Res. 2002;  62 3448-52.
• 15 Ju Y H, Doerge D R, Allred K F, Allred C D, Helferich W G. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice.  Cancer Res. 2002;  62 2474-7.
• 16 Jones J L, Daley B J, Enderson B L, Zhou J R, Karlstad M D. Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells.  Am Surg. 2002;  68 575-7.
• 17 Russo J, Russo I H. Biology of disease: biological and molecular bases of mammary carcinogenesis.  Lab Invest. 1987;  57 112-37.
• 18 Russo I H, Tewari M, Russo J. Morphology and development of the rat mammary gland. In: Jones TC, Mohr U, Hunt RD Integument and mammary gland of laboratory animals. Berlin; Springer Verlag 1989: 233-52.
• 19 Russo I H, Medado J, Russo J. Endocrine influences on mammary structure and development. In: Jones TC, Mohr U, Hunt RD Integument and mammary gland of laboratory animals. Berlin; Springer Verlag 1989: 252-66.
• 20 Russo J, Gusterson B A, Rogers A E, Russo I H, Wellings S R, van Zwieten M J. Biology of disease: Comparative study of human and rat mammary tumorigenesis.  Lab Invest. 1990;  62 244-78.
• 21 Spinola P G, Marchetti B, Mérand Y, Bélanger A, Labrie F. Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors.  Breast Cancer Res Treat. 1988;  12 287-96.
• 22 Zhou J L, Brodie A. The effect of aromatase inhibitor 4-hydroxyandrostenedione on steroid receptors in hormone-dependent tissues of the rat.  J Steroid Biochem Mol Biol. 1995;  52 71-6.
• 23 Wing L Y, Garrett W M, Brodie A M. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione, on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.  Cancer Res. 1985;  45 2425-8.
• 24 Carlini P, Frassoldati A, De Marco S, Casali A, Ruggeri E M, Nardi M. et al . Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable?.  Ann Oncol. 2001;  12 1539-43.